Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Overweight × Bupropion × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Uterine Cervical Neoplasms 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urinary Bladder Neoplasms 1 Tobacco Use Disorder 1 Stomach Neoplasms 1 Smoking Cessation 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Overweight 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Obesity 1 Neoplasms, Second Primary 1 Nasopharyngeal Neoplasms 1 Mouth Neoplasms 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Laryngeal Neoplasms 1 Kidney Neoplasms 1 Hypopharyngeal Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Behavior, Addictive 1

Interventions

licogliflozin 1 bupropion hydrochloride, naltrexone hydrochoride drug combination 1 Naltrexone 1 Exercise 1 Exenatide 1 Diet, Plant-Based 1 Counseling 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04499950 2025-03-06

A-NEW

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

53 enrolled 14 charts

Breast Neoplasms, Obesity, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon ⚡